| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,890,000 |
| Market
Cap: |
37.18(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.51 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
122,000 |
248,000 |
500,000 |
584,000 |
| Total Sell Value |
$252,439 |
$623,979 |
$2,056,681 |
$2,685,347 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
5 |
11 |
27 |
35 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Satter Muneer A |
Director |
– • • |
2018-12-11 |
4 |
B |
$2.09 |
$41,846 |
I/I |
20,000 |
5,258,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-12-10 |
4 |
B |
$2.13 |
$42,608 |
I/I |
20,000 |
5,238,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-12-07 |
4 |
B |
$2.14 |
$42,788 |
I/I |
20,000 |
5,218,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-12-06 |
4 |
B |
$2.18 |
$43,584 |
I/I |
20,000 |
5,198,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-12-04 |
4 |
B |
$2.10 |
$41,994 |
I/I |
20,000 |
5,178,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-12-03 |
4 |
B |
$1.99 |
$39,774 |
I/I |
20,000 |
5,158,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-11-30 |
4 |
B |
$1.98 |
$39,692 |
I/I |
20,000 |
5,138,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-11-29 |
4 |
B |
$2.01 |
$40,118 |
I/I |
20,000 |
5,118,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-11-28 |
4 |
B |
$1.94 |
$38,714 |
I/I |
20,000 |
5,098,017 |
2.25 |
- |
|
| Hoffman Stephen J |
Chief Executive Officer |
• • – |
2018-11-12 |
4 |
B |
$2.01 |
$60,300 |
D/D |
30,000 |
31,967 |
2.81 |
- |
|
| Hoffman Stephen J |
Chief Executive Officer |
• • – |
2018-11-09 |
4 |
B |
$1.95 |
$3,836 |
D/D |
1,967 |
1,967 |
2.73 |
- |
|
| Castelein Caley |
Director |
– • – |
2018-09-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,603,526) |
0 |
|
- |
|
| Castelein Caley |
Director |
– • – |
2018-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
268,987 |
279,907 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2018-08-20 |
4 |
S |
$3.90 |
$20,670 |
I/I |
(5,300) |
5,800,250 |
|
- |
|
| Khuong Chau Quang |
Director |
– • • |
2018-06-28 |
4 |
B |
$3.85 |
$2,993,375 |
I/I |
777,500 |
5,193,946 |
2.25 |
- |
|
| Orbimed Capital Gp V Llc |
Director |
– • • |
2018-06-28 |
4 |
B |
$3.85 |
$2,993,375 |
I/I |
777,500 |
5,193,946 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-06-28 |
4 |
B |
$3.85 |
$7,000,001 |
I/I |
1,818,182 |
5,078,017 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-03-23 |
4 |
B |
$5.00 |
$5,000 |
I/I |
1,000 |
3,259,835 |
2.17 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-03-21 |
4 |
B |
$4.85 |
$19,390 |
I/I |
4,000 |
3,258,835 |
2.17 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-03-20 |
4 |
B |
$4.97 |
$26,860 |
I/I |
5,400 |
3,254,835 |
2.25 |
- |
|
| Satter Muneer A |
Director |
– • • |
2018-03-19 |
4 |
B |
$4.96 |
$37,725 |
I/I |
7,600 |
3,249,435 |
2.25 |
- |
|
| Gardner Joseph H. |
See RemarksOfficer |
• • – |
2017-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
493,023 |
|
- |
|
| Khuong Chau Quang |
Director |
– • • |
2017-03-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,653,451 |
|
- |
|
| Peters Kevin G. |
Chief Scientific OfficerOffice |
• – – |
2017-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
316,894 |
|
- |
|
| Weiss Paul M |
Director |
– • – |
2017-03-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,303,865 |
|
- |
|
138 Records found
|
|
Page 5 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (5.32%) 
